New Research Finds Phase 3 is the Most Popular Stage for Medical Affairs Teams to Begin Thought Leader Development Activities
May 08, 2017 19:30 ET
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - May 08, 2017) - Between both Phase 3a and 3b, 50% of surveyed teams begin their thought leader development activities, with the next most popular stage to...
FMV Budget is a Top Criterion Among Surveyed Companies When Evaluating IIT Proposals
February 21, 2017 08:36 ET
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - February 21, 2017) - Nearly one-third of surveyed pharmaceutical companies look to fair-market value (FMV) budget as one their most important criteria for...
Medical Affairs Teams Undertake Launch Planning Activities as Early as Three Years Ahead of Product Launch, Says New Research
January 26, 2017 07:39 ET
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - January 26, 2017) - Launch planning is an essential component of life science teams' ongoing activities. As new life science products approach the launch...
Pharma to Clinical Investigators: Reach Target Patient Enrollment or You Don't Get Paid
October 11, 2016 09:08 ET
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - October 11, 2016) - A study published by Cutting Edge Information found that 87% of surveyed pharmaceutical companies would not submit next-level clinical...
77% of Investigator-Initiated Trial Committees With Complete Voting Privileges Let High-Level Executives Make Final Decisions
June 28, 2016 08:17 ET
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - June 28, 2016) - Investigator-initiated trial (IIT) review committees are often small and contain individuals from a variety of backgrounds. Most...
75 Percent of Drug Companies Formally Manage Investigator-Initiated Trials
March 03, 2010 09:17 ET
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwire - March 3, 2010) - Investigator-initiated trials (IITs) provide companies with clinical data to expand scientific understanding of their drugs and reap a...